ID: ALA1098136

Max Phase: Preclinical

Molecular Formula: C10H13IN2O4

Molecular Weight: 352.13

Molecule Type: Small molecule

Representations

Canonical SMILES:  Cc1cn([C@H]2C[C@H](I)[C@@H](CO)O2)c(=O)[nH]c1=O

Standard InChI:  InChI=1S/C10H13IN2O4/c1-5-3-13(10(16)12-9(5)15)8-2-6(11)7(4-14)17-8/h3,6-8,14H,2,4H2,1H3,(H,12,15,16)/t6-,7+,8+/m0/s1

Standard InChI Key:  RHYWJBFVIQZQQA-XLPZGREQSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 352.13

Molecular Weight (Monoisotopic): 351.9920

AlogP: -0.07

#Rotatable Bonds: 2

Polar Surface Area: 84.32

Molecular Species: NEUTRAL

HBA: 5

HBD: 2

#RO5 Violations: 0

HBA (Lipinski): 6

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 10.11

CX Basic pKa:

CX LogP: 0.67

CX LogD: 0.67

Aromatic Rings: 1

Heavy Atoms: 17

QED Weighted: 0.58

Np Likeness Score: 0.68

References

1. Herdewijn P, Balzarini J, De Clercq E, Pauwels R, Baba M, Broder S, Vanderhaeghe H..  (1987)  3'-substituted 2',3'-dideoxynucleoside analogues as potential anti-HIV (HTLV-III/LAV) agents.,  30  (8): [PMID:3497272] [10.1021/jm00391a003]

2. Chu CK, Schinazi RF, Ahn MK, Ullas GV, Gu ZP..  (1989)  Structure-activity relationships of pyrimidine nucleosides as antiviral agents for human immunodeficiency virus type 1 in peripheral blood mononuclear cells.,  32  (3): [PMID:2918508] [10.1021/jm00123a018]

3. Shakya N, Srivastav NC, Desroches N, Agrawal B, Kunimoto DY, Kumar R..  (2010)  3'-bromo analogues of pyrimidine nucleosides as a new class of potent inhibitors of Mycobacterium tuberculosis.,  53  (10): [PMID:20420370] [10.1021/jm100165w]

Source

Source(1):

• Scientific Literature